Sign in
Not yet taking people in South KoreaPhase 4

Vericiguat for Heart Failure With Leaky Tricuspid Valve and Right Heart Weakness

Tests vericiguat in adults with weak heart pumping and a leaky tricuspid valve.

Key facts

Who runs it
Daejeon St. Mary's hospital
Where
Daejeon, South KoreaSee the site
Trial code
Registry title
Efficacy of Verciguat in TR and RV Failure
Status
Not yet recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
1 Jul 2026
Expected to end
31 May 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Vericiguat
Record updated
25 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-term heart failure, weak left heart pumping and a leaky tricuspid valve, who also have right heart weakness.

Age
More than 19 years old
Sex
All sexes can join.
Disease stage
Chronic heart failure with LVEF<45%; right ventricle malfunction confirmed with EKG data or cardiac MRI; tricuspid regurgitation greater than moderate severity confirmed by echocardiogram. NTproBNP >1000, or >1600 with atrial fibrillation, or recent worsening heart failure (recent hospitalization or intravenous diuretics as an outpatient).
Earlier treatment
Must have had standard heart failure treatment for over 4 weeks. Must not have taken vericiguat in the last 6 months.
Biomarker or test result
NTproBNP >1000 (>1600 with atrial fibrillation), unless the person recently had worsening heart failure.

Main reasons for not taking part

  • Systolic blood pressure (SBP) < 100 mmHg
  • Currently treated with other sGC stimulators (including vericiguat) or PDE5 inhibitors
  • Moderate-to-severe right ventricular failure needing surgery
  • Currently pregnant or able to have children

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age more than 19 years old
  • right ventricular malfunction confirmed with EKG data or cardiac MRI
  • chronic heart failure with LVEF<45%
  • Patients Who administrated standard treatment of Heart Failur for over the 4 weeks
  • NTproBNP >1000, NTproBNP >1600 with atrial fibrillation or The patient who recently experienced worsening heart failure(Recent hospitalization for worsening heart failure or outpatient administration of intravenous diuretics)
  • Tricuspid regurgitation of greater than moderate severity was confirmed by echocardiogram
  • Subject who provided voluntary informed consent to participate in the study
  • Patients who have not been administered vericiguat within the last 6 months

Who cannot take part

  • Patients currently treated with other sGC stimulators (including vericiguat) or phosphodiesterase-5 (PDE5) inhibitors
  • Moderate-to-severe right ventricular (RV) failure requiring surgical intervention
  • Patients with a systolic blood pressure (SBP) < 100 mmHg
  • Patients who are currently pregnant or of childbearing potential

Where in South Korea

  • Daejeon St.Mary's HospitalDaejeon, South KoreaContact: Principle InvestigatorNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the drug vericiguat works to improve right heart function in patients with worsening heart failure who have reduced left ventricular function. It will also examine the effects of the drug on tricuspid regurgitation (TR) and overall clinical outcomes.

Read full original descriptionShow less

The main questions it aims to answer are:

Does vericiguat improve right ventricular (RV) function and reduce tricuspid regurgitation (TR)? Does vericiguat reduce the risk of major adverse cardiovascular events (MACE), such as heart failure hospitalizations and cardiovascular death? Does vericiguat improve participants' exercise capacity, quality of life, and renal function?

Researchers have previously seen the benefits of vericiguat in the large-scale VICTORIA trial for worsening heart failure, and it is hypothesized that improvements in right heart function play a key role. This study aims to confirm these specific benefits.

Participants will:

Take vericiguat as prescribed during the study period. Undergo echocardiograms at enrollment and at 9 months to assess right heart function.

Complete questionnaires (KCCQ-12) and walking tests (6MWT) to evaluate quality of life and exercise capacity.

Provide blood samples to monitor NTproBNP levels and renal function (creatinine).

The 2 groups in the trial

  • Arm with administered with VericiguatTreatment being tested

    Subjects assigned to the experimental arm will initiate vericiguat at a daily dose of 2.5 mg, concurrently with their baseline heart failure therapy including standard of care (loop diuretics, MRAs, and SGLT2i). The dose will be targeted to double every 2 weeks, titrating up to a maximum dose of 10 mg.

    Treatment: Vericiguat

  • Arm with standard of careNo study treatment, for comparison

    This arm is classified as the standard of care control group, where participants receive baseline heart failure therapies including loop diuretics, MRAs, and SGLT2i. During the study period, if a participant in this arm exhibits no symptomatic improvement or demonstrates clinical worsening despite baseline therapy, the investigator will re-evaluate the doses of the existing standard medications and titrate them up to the maximum recommended doses within a permissible range, or adjust the medication combination to prioritize patient safety. Additionally, in cases of accompanied fluid overload, further pharmacological interventions, including the adjustment of diuretics, may be administered.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Vericiguat in HFrEF Patients With Coexisting Severe Tricuspid Regurgitation and Right Heart Failure; Multicenter Pragmatic Randomized Controlled Trial
Plain-language title
Vericiguat for Heart Failure With Leaky Tricuspid Valve and Right Heart WeaknessGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 June 2026